Here, we describe an exploratory biomarker analysis using next-generation sequencing (NGS) of pretreatment tumor tissues to evaluate the genomic and transcriptomic profiles associated with the response to the eribulin and nivolumab combination in patients with human epidermal growth factor receptor-2 (HER-2) negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.